Now showing items 1-10 of 10

    • Advances in the Development of Molecularly Targeted Agents in Non-Small-Cell Lung Cancer. 

      Dolly, SO; Collins, DC; Sundar, R; Popat, S; Yap, TA (2017-05)
      Non-small-cell lung cancer (NSCLC) remains a significant global health challenge and the leading cause of cancer-related mortality. The traditional 'one-size-fits-all' treatment approach has now evolved into one that ...
    • Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development? 

      Carden, CP; Sarker, D; Postel-Vinay, S; Yap, TA; Attard, G; Banerji, U; Garrett, MD; Thomas, GV; Workman, P; Kaye, SB; de Bono, JS (2010-02)
      Anticancer drug development remains slow, costly and inefficient. One way of addressing this might be the use of predictive biomarkers to select patients for Phase I/II trials. Such biomarkers, which predict response to ...
    • Clinical factors of response in patients with advanced ovarian cancer participating in early phase clinical trials. 

      George, A; Kristeleit, R; Rafii, S; Michie, CO; Bowen, R; Michalarea, V; van Hagen, T; Wong, M; Rallis, G; Molife, LR; Lopez, J; Banerji, U; Banerjee, SN; Gore, ME; de Bono, JS; Kaye, SB; Yap, TA (2017-05)
      Drug resistance to conventional anticancer therapies is almost inevitable in patients with advanced ovarian cancer (AOC), limiting their available treatment options. Novel phase I trial therapies within a dedicated drug ...
    • Critical parameters in targeted drug development: the pharmacological audit trail. 

      Banerji, U; Workman, P (2016-08)
      The Pharmacological Audit Trail (PhAT) comprises a set of critical questions that need to be asked during discovery and development of an anticancer drug. Key aspects include: (1) defining a patient population; (2) ...
    • The Current Landscape of Early Drug Development for Patients With Sarcoma. 

      Wilky, BA; Jones, RL; Keedy, VL (2017-01)
      Until recently, advancements in the treatment of patients with adult soft tissue sarcomas have been relatively slow. This is, in part, due to their heterogeneity and rarity. A better understanding of the biology and ...
    • Development of molecularly targeted agents and immunotherapies in small cell lung cancer. 

      Sharp, A; Bhosle, J; Abdelraouf, F; Popat, S; O'Brien, M; Yap, TA (2016-06)
      Small cell lung cancer (SCLC) is a smoking-induced malignancy with multiple toxin-associated mutations, which accounts for 15% of all lung cancers. It remains a clinical challenge with a rapid doubling time, early dissemination ...
    • Drug discovery in advanced prostate cancer: translating biology into therapy. 

      Yap, TA; Smith, AD; Ferraldeschi, R; Al-Lazikani, B; Workman, P; de Bono, JS (2016-10)
      Castration-resistant prostate cancer (CRPC) is associated with a poor prognosis and poses considerable therapeutic challenges. Recent genetic and technological advances have provided insights into prostate cancer biology ...
    • From class waivers to precision medicine in paediatric oncology. 

      Pearson, ADJ; Pfister, SM; Baruchel, A; Bourquin, J-P; Casanova, M; Chesler, L; Doz, F; Eggert, A; Geoerger, B; Jones, DTW; Kearns, PR; Molenaar, JJ; Morland, B; Schleiermacher, G; Schulte, JH; Vormoor, J; Marshall, LV; Zwaan, CM; Vassal, G; Executive and Biology Committees of the Innovative Therapies for Children with Cancer European Consortium (2017-07)
      New drugs are crucially needed for children with cancer. The European Paediatric Regulation facilitates paediatric class waivers for drugs developed for diseases only occurring in adults. In this Review, we retrospectively ...
    • Mapping genetic vulnerabilities reveals BTK as a novel therapeutic target in oesophageal cancer. 

      Chong, IY; Aronson, L; Bryant, H; Gulati, A; Campbell, J; Elliott, R; Pettitt, S; Wilkerson, P; Lambros, MB; Reis-Filho, JS; Ramessur, A; Davidson, M; Chau, I; Cunningham, D; Ashworth, A; Lord, CJ (2018-10)
      OBJECTIVE:Oesophageal cancer is the seventh most common cause of cancer-related death worldwide. Disease relapse is frequent and treatment options are limited. DESIGN:To identify new biomarker-defined therapeutic approaches ...
    • Treatment of Advanced Prostate Cancer-A Review of Current Therapies and Future Promise. 

      Sumanasuriya, S; De Bono, J (2018-06)
      Despite many recent advances in the therapy for metastatic castration-resistant prostate cancer (mCRPC), the disease remains incurable, although men suffering from this disease are living considerably longer. In this review, ...